{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:25:52Z","timestamp":1790835952980,"version":"4.1.0"},"reference-count":168,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002857","name":"China Pharmaceutical University","doi-asserted-by":"publisher","award":["S202510316001"],"award-info":[{"award-number":["S202510316001"]}],"id":[{"id":"10.13039\/501100002857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903656"],"award-info":[{"award-number":["81903656"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473966"],"award-info":[{"award-number":["82473966"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273968"],"award-info":[{"award-number":["82273968"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.drudis.2026.104599","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:22:18Z","timestamp":1767918138000},"page":"104599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Next-generation drug conjugates for breast cancer: Clinical prospects and mechanism-based strategies to overcome resistance"],"prefix":"10.1016","volume":"31","author":[{"given":"Monong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3125-0320","authenticated-orcid":false,"given":"Hongxi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104599_b0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104599_b0010","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41416-021-01564-x","article-title":"ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges","volume":"126","author":"Herzog","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2026.104599_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102952","article-title":"RelB-activated GPX4 inhibits ferroptosis and confers tamoxifen resistance in breast cancer","volume":"68","author":"Xu","year":"2023","journal-title":"Redox Biol"},{"key":"10.1016\/j.drudis.2026.104599_b0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-3-030-20301-6_4","article-title":"Breast cancer: current perspectives on the disease status","volume":"1152","author":"Ullah","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.drudis.2026.104599_b0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104599_b0030","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40265-020-01281-4","article-title":"Trastuzumab deruxtecan: first approval","volume":"80","author":"Keam","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2026.104599_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102692","article-title":"From text to insight: a natural language processing-based analysis of burst and research trends in HER2-low breast cancer patients","volume":"106","author":"Li","year":"2025","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.drudis.2026.104599_b0040","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody-drug conjugates: a review","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2026.104599_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101086","article-title":"Spotlight on ideal target antigens and resistance in antibody-drug conjugates: strategies for competitive advancement","volume":"75","author":"Jiang","year":"2024","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drudis.2026.104599_b0050","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","article-title":"Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity","volume":"77","author":"R\u00edos-Luci","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104599_b0055","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging new therapeutic antibody derivatives for cancer treatment","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104599_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117106","article-title":"Precision targeting in oncology: the future of conjugated drugs","volume":"177","author":"Li","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2026.104599_b0065","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1158\/2326-6066.CIR-21-0722","article-title":"Preclinical characterization and phase I study of an anti-HER2-TLR7 immune-stimulator antibody conjugate in patients with HER2+ malignancies","volume":"10","author":"Janku","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.drudis.2026.104599_b0070","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1038\/onc.2014.314","article-title":"Mechanism-based cancer therapy: resistance to therapy, therapy for resistance","volume":"34","author":"Ramos","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2026.104599_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216024","article-title":"An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs","volume":"554","author":"Gandullo-S\u00e1nchez","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1016\/j.drudis.2026.104599_b0080","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/978-3-031-70875-6_24","article-title":"HER2-positive breast cancer treatment and resistance","volume":"1464","author":"Veeraraghavan","year":"2025","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.drudis.2026.104599_b0085","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s13046-020-01797-3","article-title":"Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER study","volume":"39","author":"Bon","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104599_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005325","article-title":"Blocking soluble TNF\u03b1 sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression","volume":"11","author":"Bruni","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.drudis.2026.104599_b0095","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2026.104599_b0100","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.trecan.2023.11.001","article-title":"Targeting HER2 heterogeneity in breast and gastrointestinal cancers","volume":"10","author":"Valenza","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.drudis.2026.104599_b0105","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.19.00882","article-title":"Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study","volume":"37","author":"Hurvitz","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104599_b0110","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","article-title":"Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab","volume":"11","author":"Filho","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2026.104599_b0115","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13058-017-0900-z","article-title":"Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers","volume":"19","author":"Baldassarre","year":"2017","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.drudis.2026.104599_b0120","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/1541-7786.MCR-19-0856","article-title":"Hypoxia attenuates trastuzumab uptake and trastuzumab-emtansine (T-DM1) cytotoxicity through redistribution of phosphorylated caveolin-1","volume":"18","author":"Indira Chandran","year":"2020","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.drudis.2026.104599_b0125","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1038\/s41467-022-30142-9","article-title":"Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer","volume":"13","author":"Pereira","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104599_b0130","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.trecan.2023.09.013","article-title":"Linking ABC transporters to the hallmarks of cancer","volume":"10","author":"Duvivier","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.drudis.2026.104599_b0135","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1158\/1535-7163.MCT-16-0219","article-title":"Combining ABCG2 inhibitors with IMMU-132, an anti-Trop-2 antibody conjugate of SN-38, overcomes resistance to SN-38 in breast and gastric cancers","volume":"15","author":"Chang","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2026.104599_b0140","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1158\/1535-7163.MCT-17-0296","article-title":"Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells","volume":"17","author":"Li","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2026.104599_b0145","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1158\/1078-0432.CCR-14-2035","article-title":"A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin-based ADCs","volume":"21","author":"Yu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104599_b0150","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/cas.13253","article-title":"Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells","volume":"108","author":"Wang","year":"2017","journal-title":"Cancer Sci"},{"key":"10.1016\/j.drudis.2026.104599_b0155","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1158\/1078-0432.CCR-18-1300","article-title":"SLC46A3 as a potential predictive biomarker for antibody-drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads","volume":"24","author":"Kinneer","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104599_b0160","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/acs.molpharmaceut.2c00741","article-title":"Identification of 5-carboxyfluorescein as a probe substrate of SLC46A3 and its application in a fluorescence-based in vitro assay evaluating the interaction with SLC46A3","volume":"20","author":"Tomabechi","year":"2023","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2026.104599_b0165","first-page":"1003","article-title":"T-DM1-resistant cells gain high invasive activity via EGFR and integrin cooperated pathways","volume":"10","author":"Endo","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.drudis.2026.104599_b0170","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ebiom.2019.04.061","article-title":"Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1","volume":"43","author":"Islam","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.drudis.2026.104599_b0175","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2146\/ajhp060612","article-title":"Fatal hypersensitivity reaction to gemtuzumab ozogamicin associated with platelet transfusion","volume":"64","author":"Hanbali","year":"2007","journal-title":"Am J Health-Syst Pharm"},{"key":"10.1016\/j.drudis.2026.104599_b0180","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.apsb.2020.04.012","article-title":"Recent advances of antibody drug conjugates for clinical applications","volume":"10","author":"Zhao","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2026.104599_b0185","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/S1470-2045(17)30845-8","article-title":"Brentuximab vedotin for advanced Hodgkin\u2019s lymphoma","volume":"18","author":"Fanale","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2026.104599_b0190","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1021\/jm500766w","article-title":"Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer","volume":"57","author":"Lambert","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104599_b0195","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1158\/2159-8290.CD-24-0644","article-title":"Tuning responses to polatuzumab vedotin in B-cell lymphoma","volume":"14","author":"Leveille","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2026.104599_b0200","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40265-021-01550-w","article-title":"Loncastuximab tesirine: first approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2026.104599_b0205","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s40265-021-01614-x","article-title":"Disitamab vedotin: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2026.104599_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103023","article-title":"Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives","volume":"140","author":"Di Lauro","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.drudis.2026.104599_b0215","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3390\/cancers14010154","article-title":"Novel ADCs and strategies to overcome resistance to anti-HER2 ADCs","volume":"14","author":"D\u00edaz-Rodr\u00edguez","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2026.104599_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104241","article-title":"Antibody-drug conjugates: prospects for the next generation","volume":"29","author":"Grairi","year":"2024","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104599_b0225","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104599_b0230","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/acs.jmedchem.2c01791","article-title":"Degrader-antibody conjugates: emerging new modality","volume":"66","author":"Hong","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104599_b0235","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.drudis.2026.104599_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117212","article-title":"Recent advances in developing targeted protein degraders","volume":"284","author":"Cheng","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104599_b0245","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cmdc.201900497","article-title":"Antibody conjugation of a chimeric BET degrader enables in\u2005vivo activity","volume":"15","author":"Pillow","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2026.104599_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108725","article-title":"Powering up targeted protein degradation through active and passive tumour-targeting strategies: current and future scopes","volume":"263","author":"Venkatesan","year":"2024","journal-title":"Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.drudis.2026.104599_b0255","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1182\/blood-2022-168936","article-title":"ORM-6151: a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader for AML","volume":"140","author":"Palacino","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2026.104599_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107469","article-title":"Overcoming limitations and advancing the therapeutic potential of antibody-oligonucleotide conjugates (AOCs): current status and future perspectives","volume":"209","author":"Jiao","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2026.104599_b0265","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1093\/nar\/gkad415","article-title":"Targeted tissue delivery of RNA therapeutics using antibody-oligonucleotide conjugates (AOCs)","volume":"51","author":"Malecova","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2026.104599_b0270","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/d41573-021-00213-5","article-title":"Antibody-oligonucleotide conjugates enter the clinic","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"13 Suppl","key":"10.1016\/j.drudis.2026.104599_b0275","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1158\/1538-7445.AM2021-1721","article-title":"Abstract 1721: TAC-001, a toll-like receptor 9 (TLR9) agonist antibody conjugate targeting B cells, promotes anti-tumor immunity and favorable safety profile following systemic administration in preclinical models","volume":"81","author":"Kuo","year":"2021","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.drudis.2026.104599_b0280","first-page":"1121","article-title":"TAC-003, a TLR9 agonist antibody conjugate for targeted immunotherapy of Nectin-4 expressing tumors","volume":"11","author":"Chen","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.drudis.2026.104599_b0285","first-page":"780","article-title":"ALTA-002, a SIRP\u03b1-directed TLR9 agonist antibody conjugate activates myeloid cells and promotes anti-tumor immunity","volume":"9","author":"Harrabi","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"8 Suppl 2","key":"10.1016\/j.drudis.2026.104599_b0290","article-title":"Abstract CT045: a phase 1\/2 trial of TAC-001 (TLR9 agonist-CD22 mAb) in advanced or metastatic solid tumors","volume":"85","author":"Henry","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104599_b0295","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s43018-020-00152-x","article-title":"ISACs take a toll on tumors","volume":"2","author":"Demaria","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.drudis.2026.104599_b0300","doi-asserted-by":"crossref","first-page":"14832","DOI":"10.1021\/acs.jmedchem.2c01351","article-title":"Enhanced immunotherapy based on combining the pro-phagocytosis and anti-phagocytosis checkpoint blockade for tumor eradication","volume":"65","author":"Song","year":"2022","journal-title":"J Med Chem"},{"issue":"15 Suppl","key":"10.1016\/j.drudis.2026.104599_b0305","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.2020.38.15_suppl.3110","article-title":"SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist","volume":"38","author":"Metz","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.drudis.2026.104599_b0310","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2021.39.15_suppl.2549","article-title":"Preliminary results from a phase I\/II study of BDC-1001, a novel HER2 targeting TLR7\/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors","volume":"39","author":"Sharma","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104599_b0315","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","article-title":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity","volume":"2","author":"Ackerman","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.drudis.2026.104599_b0320","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-24-2449","article-title":"XMT-2056, a HER2-directed STING agonist antibody-drug conjugate, induces innate anti-tumor immune responses by acting on cancer cells and tumor-resident immune cells","volume":"31","author":"Bukhalid","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104599_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107160","article-title":"When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?","volume":"203","author":"Fu","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2026.104599_b0330","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.869639","article-title":"Synthesis and evaluation of a non-peptide small-molecule drug conjugate targeting integrin \u03b1V\u03b23","volume":"10","author":"Paulus","year":"2022","journal-title":"Front Chem"},{"key":"10.1016\/j.drudis.2026.104599_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2024.110799","article-title":"Small molecule-drug conjugates: mechanistic insights and strategic design for enhanced cancer therapy","volume":"36","author":"Zhu","year":"2025","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.drudis.2026.104599_b0340","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2026.104599_b0345","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1158\/1078-0432.CCR-19-0551","article-title":"OBI-3424, a novel AKR1C3-activated prodrug, exhibits potent efficacy against preclinical models of T-ALL","volume":"25","author":"Evans","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104599_b0350","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3390\/cancers14020391","article-title":"A small molecule-drug conjugate (SMDC) consisting of a modified camptothecin payload linked to an \u03b1V\u00df3 binder for the treatment of multiple cancer types","volume":"14","author":"Lerchen","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2026.104599_b0355","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.3390\/cancers15174381","article-title":"Discovery of VIP236, an \u03b1v\u03b23-targeted small-molecule-drug conjugate with neutrophil elastase-mediated activation of 7-ethyl camptothecin payload for treatment of solid tumors","volume":"15","author":"Lerchen","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2026.104599_b0360","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1186\/s12885-025-14282-x","article-title":"Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases","volume":"25","author":"Taiwo","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drudis.2026.104599_b0365","article-title":"Carbonic anhydrase IX-targeted SMDCs for cancer precision treatment","author":"Zhang","year":"2025","journal-title":"Chin Chem Lett."},{"key":"10.1016\/j.drudis.2026.104599_b0370","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1016\/j.apsb.2023.02.013","article-title":"Research advances in peptide-drug conjugates","volume":"13","author":"Gong","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2026.104599_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103353","article-title":"Advancement of cell-penetrating peptides in combating triple-negative breast cancer","volume":"27","author":"Fatima","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104599_b0380","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2174\/0929866525666180530122835","article-title":"Optimization of protein and peptide drugs based on the mechanisms of kidney clearance","volume":"25","author":"Wu","year":"2018","journal-title":"Protein Pept Lett"},{"key":"10.1016\/j.drudis.2026.104599_b0385","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/acs.molpharmaceut.9b00188","article-title":"Targeted delivery of a ligand-drug conjugate via formyl peptide receptor 1 through cholesterol-dependent endocytosis","volume":"16","author":"Wang","year":"2019","journal-title":"Mol Pharm"},{"issue":"16 Suppl","key":"10.1016\/j.drudis.2026.104599_b0390","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1200\/JCO.2023.41.16_suppl.5577","article-title":"First-in-human, phase I study of CBP-1008, a bi-specific ligand drug conjugate, in patients with advanced solid tumors","volume":"41","author":"Gong","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104599_b0395","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-19-3258","article-title":"ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases","volume":"26","author":"Kumthekar","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104599_b0400","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1111\/cas.15086","article-title":"TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer","volume":"112","author":"Demeule","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.drudis.2026.104599_b0405","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1016\/j.apsb.2024.04.007","article-title":"Characteristic roadmap of linker governs the rational design of PROTACs","volume":"14","author":"Dong","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2026.104599_b0410","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.2147\/DDDT.S135571","article-title":"Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates","volume":"11","author":"Kalim","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.drudis.2026.104599_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116216","article-title":"What influences the activity of degrader-antibody conjugates (DACs)","volume":"268","author":"Guo","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104599_b0420","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1039\/D2CS00141A","article-title":"Degrader-antibody conjugates","volume":"51","author":"Dragovich","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.drudis.2026.104599_b0425","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.scib.2024.03.056","article-title":"Targeting the undruggables\u2014the power of protein degraders","volume":"69","author":"Zhang","year":"2024","journal-title":"Sci Bull"},{"key":"10.1016\/j.drudis.2026.104599_b0430","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41419-025-07535-x","article-title":"Decoy-PROTAC for specific degradation of \u201cundruggable\u201d STAT3 transcription factor","volume":"16","author":"Li","year":"2025","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2026.104599_b0435","doi-asserted-by":"crossref","first-page":"19010","DOI":"10.1021\/acs.jmedchem.4c01521","article-title":"Discovery of ERD-1233 as a potent and orally efficacious estrogen receptor PROTAC degrader for the treatment of ER+ human breast cancer","volume":"67","author":"Acharyya","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104599_b0440","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202100270","article-title":"Recent developments in PROTAC\u2010mediated protein degradation: from bench to clinic","volume":"23","author":"Hu","year":"2022","journal-title":"ChemBioChem"},{"key":"10.1016\/j.drudis.2026.104599_b0445","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104599_b0450","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41467-023-44533-z","article-title":"The HER2-directed antibody-drug conjugate DHES0815A in advanced and\/or metastatic breast cancer: preclinical characterization and phase 1 trial results","volume":"15","author":"Lewis","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104599_b0455","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3390\/jcm10040838","article-title":"Antibody-oligonucleotide conjugates: a twist to antibody-drug conjugates","volume":"10","author":"Dugal-Tessier","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.drudis.2026.104599_b0460","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2026.104599_b0465","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1021\/acs.bioconjchem.9b00306","article-title":"Antibody-oligonucleotide conjugates as therapeutic, imaging, and detection agents","volume":"30","author":"Dovgan","year":"2019","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.drudis.2026.104599_b0470","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.drudis.2022.03.014","article-title":"New therapy strategies in the management of breast cancer","volume":"27","author":"Yardim-Akaydin","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104599_b0475","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211041453","article-title":"Cetuximab-siRNA conjugate linked through cationized gelatin knocks down KRAS G12C mutation in NSCLC sensitizing the cells toward gefitinib","volume":"20","author":"Sreedurgalakshmi","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.drudis.2026.104599_b0480","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104599_b0485","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3389\/fimmu.2020.01393","article-title":"Fc gamma receptors and their role in antigen uptake, presentation, and T cell activation","volume":"11","author":"Junker","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104599_b0490","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.2147\/IJGM.S408349","article-title":"Immune checkpoint inhibitor-based combination therapy for colorectal cancer: an overview","volume":"16","author":"Li","year":"2023","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.drudis.2026.104599_b0495","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000940","article-title":"In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy","volume":"8","author":"Cheng","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.drudis.2026.104599_b0500","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011651","article-title":"Phase 1b\/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors","volume":"13","author":"Milhem","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.drudis.2026.104599_b0505","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","article-title":"Overcoming PD-1 blockade resistance with CpG-a toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2026.104599_b0510","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1021\/acs.jmedchem.1c00003","article-title":"Enhancing the pharmacokinetics and antitumor activity of an \u03b1-amanitin-based small-molecule drug conjugate via conjugation with an Fc domain","volume":"64","author":"Gallo","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104599_b0515","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1021\/acs.molpharmaceut.3c01049","article-title":"Small molecule-drug conjugates emerge as a new promising approach for cancer treatment","volume":"21","author":"Wang","year":"2024","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2026.104599_b0520","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jconrel.2024.02.014","article-title":"In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment","volume":"367","author":"Bocci","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2026.104599_b0525","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3390\/ijms24010829","article-title":"Peptide drug conjugates and their role in cancer therapy","volume":"24","author":"Heh","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104599_b0530","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4155\/fmc-2017-0008","article-title":"RGD-mediated delivery of small-molecule drugs","volume":"9","author":"Katsamakas","year":"2017","journal-title":"Future Med Chem"},{"key":"10.1016\/j.drudis.2026.104599_b0535","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1021\/acs.molpharmaceut.3c00189","article-title":"Peptide-drug conjugate targeting keratin 1 inhibits triple-negative breast cancer in mice","volume":"20","author":"Ziaei","year":"2023","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2026.104599_b0540","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1080\/10717544.2018.1435746","article-title":"Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer","volume":"25","author":"You","year":"2018","journal-title":"Drug Deliv"},{"key":"10.1016\/j.drudis.2026.104599_b0545","doi-asserted-by":"crossref","first-page":"5646","DOI":"10.1158\/1538-7445.AM2025-5646","article-title":"Abstract 5646: a novel in vivo self-assembled peptide-drug conjugate targeting HER2 with potent anti-tumor efficacy overcoming resistance of HER2 ADCs","volume":"85","author":"Lyu","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104599_b0550","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172156","article-title":"Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response","volume":"133","author":"Chang","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2026.104599_b0555","first-page":"1643","article-title":"Matrix metalloproteinases-2\/9-sensitive peptide-conjugated polymer micelles for site-specific release of drugs and enhancing tumor accumulation: preparation and in vitro and in vivo evaluation","volume":"11","author":"Zhang","year":"2016","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.drudis.2026.104599_b0560","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2021.1965418","article-title":"Cell-penetrating peptides improve pharmacokinetics and pharmacodynamics of anticancer drugs","volume":"10","author":"Rusiecka","year":"2022","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.drudis.2026.104599_b0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100905","article-title":"ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance","volume":"66","author":"Fan","year":"2023","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drudis.2026.104599_b0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113050","article-title":"Discovery of novel cell-penetrating and tumor-targeting peptide-drug conjugate (PDC) for programmable delivery of paclitaxel and cancer treatment","volume":"213","author":"Deng","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104599_b0575","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1124\/pharmrev.121.000499","article-title":"New technologies bloom together for bettering cancer drug conjugates","volume":"74","author":"Jin","year":"2022","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.drudis.2026.104599_b0580","doi-asserted-by":"crossref","first-page":"22399","DOI":"10.1021\/acsnano.3c04718","article-title":"Macrocyclic-albumin conjugates for precise delivery of radionuclides and anticancer drugs to tumors","volume":"17","author":"Li","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.drudis.2026.104599_b0585","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/med.22093","article-title":"Comparison of radionuclide drug conjugates with boron neutron capture therapy: an overview of targeted charged particle radiation therapy","volume":"45","author":"Zhang","year":"2025","journal-title":"Med Res Rev"},{"key":"10.1016\/j.drudis.2026.104599_b0590","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.3390\/molecules28062605","article-title":"Antibody-biopolymer conjugates in oncology: a review","volume":"28","author":"Chavda","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2026.104599_b0595","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1158\/0008-5472.CAN-18-0238","article-title":"Bicyclic peptides as a new modality for imaging and targeting of proteins overexpressed by tumors","volume":"79","author":"Eder","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104599_b0600","doi-asserted-by":"crossref","first-page":"8268","DOI":"10.1038\/s41467-023-43847-2","article-title":"Anti-VEGFR2 F(ab\u2032)2 drug conjugate promotes renal accumulation and glomerular repair in diabetic nephropathy","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104599_b0605","doi-asserted-by":"crossref","first-page":"9347","DOI":"10.1021\/acs.analchem.3c01426","article-title":"Added value of internal fragments for top-down mass spectrometry of intact monoclonal antibodies and antibody-drug conjugates","volume":"95","author":"Wei","year":"2023","journal-title":"Anal Chem"},{"key":"10.1016\/j.drudis.2026.104599_b0610","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2026.104599_b0615","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/s41467-018-04982-3","article-title":"Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice","volume":"9","author":"Anami","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104599_b0620","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.drudis.2026.104599_b0625","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/14789450.2019.1578215","article-title":"Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future","volume":"16","author":"Beck","year":"2019","journal-title":"Expert Rev Proteomics"},{"key":"10.1016\/j.drudis.2026.104599_b0630","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1021\/acs.jmedchem.7b01430","article-title":"Discovery of peptidomimetic antibody-drug conjugate linkers with enhanced protease specificity","volume":"61","author":"Wei","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104599_b0635","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1039\/C9SC03016F","article-title":"A light-responsive, self-immolative linker for controlled drug delivery via peptide- and protein-drug conjugates","volume":"10","author":"Zang","year":"2019","journal-title":"Chem Sci"},{"key":"10.1016\/j.drudis.2026.104599_b0640","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1021\/acs.molpharmaceut.8b00242","article-title":"Toward a ferrous iron-cleavable linker for antibody-drug conjugates","volume":"15","author":"Spangler","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2026.104599_b0645","doi-asserted-by":"crossref","first-page":"17133","DOI":"10.1021\/jacs.9b05833","article-title":"Copper-triggered bioorthogonal cleavage reactions for reversible protein and cell surface modifications","volume":"141","author":"Wang","year":"2019","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2026.104599_b0650","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1158\/1535-7163.MCT-24-0052","article-title":"Targeting tumor antigen 5T4 using CAR-T cells for the treatment of acute myeloid leukemia","volume":"24","author":"Harrop","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2026.104599_b0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.140525","article-title":"Chemoenzymatic liquid-phase synthesis and immunogenic assessment of tumor-associated complex MUC1 glycopeptide variants","volume":"302","author":"Teng","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2026.104599_b0660","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41420-024-02239-1","article-title":"Therapeutic advances in the targeting of ROR1 in hematological cancers","volume":"10","author":"Tigu","year":"2024","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.drudis.2026.104599_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116927","article-title":"Impact of site-specific conjugation strategies on the pharmacokinetics of antibody conjugated radiotherapeutics","volume":"280","author":"Nagy","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104599_b0670","article-title":"An antibody-drug conjugate for multiple myeloma prepared by multi-arm linkers","volume":"11","author":"Yu","year":"2024","journal-title":"Adv Sci"},{"issue":"Suppl 2","key":"10.1016\/j.drudis.2026.104599_b0675","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.annonc.2024.08.714","article-title":"An open-label, MRCT phase I\/II study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of first-in-class bi-ligand-drug conjugate CBP-1019 in patients (pts) with advanced solid tumors","volume":"35","author":"Liu","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2026.104599_b0680","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1021\/acs.molpharmaceut.8b00177","article-title":"Impact of payload hydrophobicity on the stability of antibody-drug conjugates","volume":"15","author":"Buecheler","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2026.104599_b0685","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202300377","article-title":"Organic\u2010solvent\u2010free \u201cLego\u2010like\u201d modular preparation of Fab\u2010nondestructive antibody-drug conjugates with ultrahigh drug\u2010to\u2010antibody ratio","volume":"35","author":"Liu","year":"2023","journal-title":"Adv Mater"},{"key":"10.1016\/j.drudis.2026.104599_b0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2023.102134","article-title":"Preparation of trastuzumab-DM1 conjugate with a high drug-to-antibody ratio for breast cancer therapy","volume":"54","author":"Zhang","year":"2024","journal-title":"Nano Today"},{"key":"10.1016\/j.drudis.2026.104599_b0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107504","article-title":"Synthesis and evaluation of antibody-drug conjugates with high drug-to-antibody ratio using dimaleimide-DM1 as a linker- payload","volume":"149","author":"Jeon","year":"2024","journal-title":"Bioorganic Chem"},{"key":"10.1016\/j.drudis.2026.104599_b0700","first-page":"11","article-title":"Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing","volume":"8","author":"Larose","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.drudis.2026.104599_b0705","first-page":"29","article-title":"Antibody-drug conjugates in breast cancer: current resistance mechanisms and future combination strategies","volume":"8","author":"Xing","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.drudis.2026.104599_b0710","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaf228","article-title":"ADCNet: a unified framework for predicting the activity of antibody-drug conjugates","volume":"26","author":"Chen","year":"2025","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.drudis.2026.104599_b0715","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-021-00666-5","article-title":"A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models","volume":"6","author":"Fan","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104599_b0720","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41401-023-01200-9","article-title":"A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity","volume":"45","author":"Zhu","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.drudis.2026.104599_b0725","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/1078-0432.CCR-12-0290","article-title":"Brentuximab vedotin","volume":"19","author":"Deng","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104599_b0730","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40265-013-0050-2","article-title":"Trastuzumab emtansine: first global approval","volume":"73","author":"Ballantyne","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2026.104599_b0735","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40272-024-00634-w","article-title":"Inotuzumab ozogamicin: first pediatric approval","volume":"26","author":"Dhillon","year":"2024","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.drudis.2026.104599_b0740","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-018-1000-9","article-title":"Moxetumomab pasudotox: first global approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2026.104599_b0745","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s40265-019-01175-0","article-title":"Polatuzumab vedotin: first global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2026.104599_b0750","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41585-024-00858-y","article-title":"Pembrolizumab plus enfortumab vedotin in urothelial cancer","volume":"21","author":"Santoni","year":"2024","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.drudis.2026.104599_b0755","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2026.104599_b0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2024.102497","article-title":"Recent strides in macromolecular targeted photodynamic therapy for cancer","volume":"81","author":"Quaye","year":"2024","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.drudis.2026.104599_b0765","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s40265-021-01633-8","article-title":"Tisotumab vedotin: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2026.104599_b0770","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1358\/dot.2022.58.5.3400745","article-title":"Tisotumab vedotin for the treatment of cervical carcinoma","volume":"58","author":"Song","year":"2022","journal-title":"Drugs Today"},{"key":"10.1016\/j.drudis.2026.104599_b0775","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13045-025-01686-2","article-title":"Mirvetuximab soravtansine: current and future applications","volume":"18","author":"Kong","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2026.104599_b0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104550","article-title":"Cost-effectiveness of sacituzumab tirumotecan versus chemotherapy for patients with metastatic triple-negative breast cancer in China","volume":"83","author":"Shu","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.drudis.2026.104599_b0785","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41571-025-01051-9","article-title":"Evolving roles of MET as a therapeutic target in NSCLC and beyond","volume":"22","author":"Lee","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104599_b0790","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1470-2045(25)00065-8","article-title":"Trastuzumab rezetecan, a new antibody-drug conjugate in HER2-mutated NSCLC","volume":"26","author":"Brueckl","year":"2025","journal-title":"Lancet Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.drudis.2026.104599_b0795","article-title":"A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors","volume":"41","author":"Hurvitz","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.drudis.2026.104599_b0800","article-title":"A phase 1\/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers","volume":"9","author":"Klempner","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.drudis.2026.104599_b0805","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011572","article-title":"Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies","volume":"13","author":"Jacoby","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"16 Suppl","key":"10.1016\/j.drudis.2026.104599_b0810","article-title":"Phase 1a\/1b study design of the novel STING agonist, immune-stimulating antibody-conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors","volume":"40","author":"Diamond","year":"2022","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.drudis.2026.104599_b0815","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1200\/JCO.2020.38.15_suppl.3515","article-title":"Pen-866, a miniature drug conjugate of a heat shock protein 90 (HSP90) ligand linked to SN38 for patients with advanced solid malignancies: phase I and expansion cohort results","volume":"38","author":"Falchook","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104599_b0820","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/bdd.2385","article-title":"Characterization of AST-001 non-clinical pharmacokinetics: a novel selective AKR1C3-activated prodrug in mice, rats, and cynomolgus monkeys","volume":"45","author":"Meng","year":"2024","journal-title":"Biopharm Drug Dispos"},{"issue":"16 Suppl","key":"10.1016\/j.drudis.2026.104599_b0825","article-title":"Phase I multicenter, open-label, dose escalation study of T-1201, a small molecule drug conjugate, to assess safety, pharmacokinetics, and antitumor activity in advanced solid tumors","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104599_b0830","article-title":"Phase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma","volume":"6","author":"Dmello","year":"2024","journal-title":"Neuro-Oncol Adv"},{"issue":"Suppl 5","key":"10.1016\/j.drudis.2026.104599_b0835","article-title":"Pharmacokinetic (PK) assessment of BT1718: a phase I\/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid tumours","volume":"30","author":"Cook","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2026.104599_b0840","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.3390\/ijms26146815","article-title":"Innovative peptide therapeutics in the pipeline: transforming cancer detection and treatment","volume":"26","author":"Nsereko","year":"2025","journal-title":"Int J Mol Sci"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:44:26Z","timestamp":1778802266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626000048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":168,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1359644626000048"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104599","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation drug conjugates for breast cancer: Clinical prospects and mechanism-based strategies to overcome resistance","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104599","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104599"}}